Global Age Related Macular Degeneration Market Size 2024, Forecast To 2033

6 Mar, 2024

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.17 billion in 2023 to $9.9 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to aging population demographics, changing lifestyles and environmental factors, genetic predisposition, increased awareness and early diagnosis, advancements in diagnostic techniques.. The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.1 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to research in genetics and biomarkers, emerging therapeutic modalities, telemedicine and remote monitoring, patient advocacy and education.. Major trends in the forecast period include personalized medicine approaches, innovations in retinal imaging technologies, emergence of sustained drug delivery systems, clinical trials for investigational therapies, collaborations for research and development..

Global Age Related Macular Degeneration Market Key Driver

Rising prevalence of age-related macular degeneration (AMD) is anticipated to fuel the expansion of the AMD market in the coming years. AMD, a progressive eye condition impacting the macula, a crucial part of the retina responsible for central vision, requires effective treatments to alleviate its severity. As reported by Optimaxa, a UK-based laser eye treatment specialist, in February 2023, AMD affected 196 million individuals globally. This figure is projected to surge to 288 million by 2040, constituting 8.7 percent of the world's population. Hence, the escalating prevalence of AMD is the driving force behind the growth of the AMD market, which is estimated to reach substantial proportions by 2028.

Get A Free Sample Of The Global Age Related Macular Degeneration Market Report

Global Age Related Macular Degeneration Market Segments

The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
By Geography:The regions covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain North America was the largest region in the global age-related macular degeneration market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Major Age Related Macular Degeneration Industry Players

F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Allergan plc, Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

Get The Full Global Age Related Macular Degeneration Market Report

Age Related Macular Degeneration Market Overview

Age-related macular degeneration (AMD) refers to a progressive eye condition in which the macula, which is located at the center of the retina, deteriorates over time in individuals with AMD, leading to a decline in central vision. It is due to aging. The therapy options for age-related macular degeneration include regular eye exams, lifestyle changes, and particular nutritional supplements.

Age Related Macular Degeneration Global Market Report 2023 provides data on the global age related macular degeneration market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The age related macular degeneration market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.